Search Results | Blood | American Society of Hematology

1-20 of 143

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Single-cell multiomics reveal the scale of multi-layered adaptations enabling CLL relapse during venetoclax therapy

Blood blood.2022016040.

DOI: https://doi.org/10.1182/blood.2022016040

Published: 2022

Includes: Supplemental data

Journal Articles

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Blood (2022) 139 (22): 3278–3289.

DOI: https://doi.org/10.1182/blood.2021014488

Published: 2022

Includes: Supplemental data

Journal Articles

Clonal hematopoiesis, myeloid disorders and BAX -mutated myelopoiesis in patients receiving venetoclax for CLL

Piers Blombery, Thomas E. Lew, Michael A. Dengler, Ella R. Thompson, Victor S. Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka M. Handunnetti, Dennis A. Carney, David A. Westerman, Constantine S. Tam, Jerry M. Adams, Andrew H. Wei, David C. S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson

Blood (2022) 139 (8): 1198–1207.

DOI: https://doi.org/10.1182/blood.2021012775

Published: 2022

Includes: Supplemental data

Journal Articles

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma

Matko Kalac, Constantine S. Tam, Mendel Goldfinger, Zhengrui Xiao, Francesca Montanari, Jennifer A. Kanakry, Owen A. O'Connor, Enrica Marchi

Blood (2021) 138 (Supplement 1): 4550.

DOI: https://doi.org/10.1182/blood-2021-144651

Published: 2021

Journal Articles

BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Anthony R. Mato, William G. Wierda, John M. Pagel, Matthew S. Davids, Pier Luigi Zinzani, Yi Lu, Hui Liu, Safi Shahda, Ching Ching Leow, Constantine S. Tam, Jennifer A. Woyach, Toby A. Eyre

Blood (2021) 138 (Supplement 1): 3742.

DOI: https://doi.org/10.1182/blood-2021-145936

Published: 2021

Journal Articles

Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Thomas Chatzikonstantinou, Lydia Scarfo, Christos Demosthenous, Jana Kotaskova, Gloria Iacoboni, Evangelia Minga, Dimitra Chammou, Georgios Karakatsoulis, Elisa Albi, Miguel Alcoceba, Shaimaa El-Ashwah, Francesca Bacchiarri, Mehreen Ali Khan, Thérèse Aurran, Anne Calleja, Ramona Cassin, Sofia Chatzileontiadou, Amy Christian, Rainer Claus, Rosa Collado, Marcos Daniel De Deus Santos, Zadie Davis, Maria Dimou, David Donaldson, Gimena Dos Santos, Barbara Dreta, Maria Efstathopoulou, Alicia Enrico, Alberto Fresa, Sara Galimberti, Rocío García-Serra, Isabel González-Gascón Y Marín, Alessandro Gozzetti, Valerio Guarente, Sean Harrop, Eleftheria Hatzimichael, Yair Herishanu, Luca Inchiappa, Michalis Iskas, Ozren Jaksic, Susanne R. Janssen, Elzbieta Kalicinska, Volkan Karakus, Arnon P. Kater, Bonnie Kho, Iliana Konstantinou, Thomas Longval, Maya Koren-Michowitz, Ioannis Kotsianidis, Robert J. Kreitman, Uttam Kumar Nath, Jorge Labrador, Deepesh Lad, Kamel Laribi, Ilana Levy, Alberto Lopez-Garcia, Juan Marquet Palomanes, Stanislava Maslejova, Carlota Mayor-Bastida, Fatiha Merabet, Biljana Mihaljevic, Ivana Milosevic, Fatima Miras, Riccardo Moia, Marta Morawska, Almudena Navarro-Bailón, David Oscier, Jacopo Olivieri, Tomáš Papajík, Maria Papaioannou, Cheyenne Pierie, Anna Puiggros, Gianluigi Reda, Gian Matteo Rigolin, Rosa Ruchlemer, Luana Schiattone, Omur Gokmen Sevindik, Yandong Shen, Martin Šimkovič, Svetlana Smirnova, Dina Sameh Soliman, Martin Špaček, Annett Schiwitza, Tamar Tadmor, Liat Tourjeman, Eric Tse, Andrea Visentin, Kristina Tomic, Michel Van Gelder, Theodoros P. Vassilakopoulos, Candida Vitale, George Vrachiolias, Vojin Vukovic, Zhenshu Xu, Lucrecia Yáñez, Munci Yagci, Mohamed A Yassin, Jana Zuchnicka, Maria K. Angelopoulou, Darko Antic, Bella V. Biderman, Mark Catherwood, Marta Coscia, Antonio Cuneo, Fatih Demirkan, Blanca Espinet, Gianluca Gaidano, Romain Guièze, Olga Kalashnikova, Luca Laurenti, Stephen Mulligan, Roberta Murru, Eugene A. Nikitin, Panayiotis Panayiotidis, Gerasimos Pangalis, Irina Panovska, Viola Maria Popov, Šárka Pospíšilová, Lukas Smolej, Paolo Sportoletti, Niki Stavroyianni, Constantine S. Tam, Livio Trentin, Marek Trněný, Francesc Bosch Albareda, Michael Doubek, Anastasia Chatzidimitriou, Paolo Ghia, Kostas Stamatopoulos

Blood (2021) 138 (Supplement 1): 2635.

DOI: https://doi.org/10.1182/blood-2021-148738

Published: 2021

Journal Articles

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Giuseppe Rossi, Henry Miles Prince, Constantine S. Tam, Matthew Ku, Catherine Thieblemont, Leslie L. Popplewell, Martin Wermke, Corinne Haioun, Nicole Wong Doo, Andreas Viardot, Andrés J M Ferreri, Silvia Ferrari, Hansen L. Wong, Priti Kadu, Gerhard Zugmaier, Yi Zeng, Alessandro Rambaldi

Blood (2021) 138 (Supplement 1): 2436.

DOI: https://doi.org/10.1182/blood-2021-152822

Published: 2021

Journal Articles

Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

Constantine S. Tam, Emma Verner, Masa Lasica, Alejandro Arbelaez, Peter J. Browett, Jacob D. Soumerai, James Hilger, Yiqian Fang, Jane Huang, David Simpson, Stephen Opat, Chan Yoon Y. Cheah

Blood (2021) 138 (Supplement 1): 1419.

DOI: https://doi.org/10.1182/blood-2021-148451

Published: 2021

Journal Articles

The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies

Chan Yoon Cheah, Wojciech Jurczak, Masa Lasica, Tomasz Wróbel, Stanley Cheung, Jan Walewski, Krzysztof Giannopoulos, Costas K. Yannakou, Katharine L Lewis, Monika Dlugosz-Danecka, Hari P. Miskin, Alejandro D. Ricart, Owen A. O'Connor, Constantine S. Tam

Blood (2021) 138 (Supplement 1): 1549.

DOI: https://doi.org/10.1182/blood-2021-145911

Published: 2021

Journal Articles

Real World Data on the Outcomes of Richter's Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study

Stephen K Walker, Sean Harrop, Pietro Di Ciaccio, Katharine Louise Lewis, Rachael Boles, Aditya Tedjaseputra, Nada Hamad, Georgina Hodges, Costas K. Yannakou, Constantine S. Tam, Stephen Opat, Chan Yoon Y. Cheah, Matthew Ku

Blood (2021) 138 (Supplement 1): 1455.

DOI: https://doi.org/10.1182/blood-2021-147146

Published: 2021

Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study

Blood (2021) 138 (Supplement 1): 381.

DOI: https://doi.org/10.1182/blood-2021-149138

Published: 2021

Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Blood (2021) 138 (Supplement 1): 391.

DOI: https://doi.org/10.1182/blood-2021-147599

Published: 2021

Journal Articles

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Blood (2021) 138 (Supplement 1): 396.

DOI: https://doi.org/10.1182/blood-2021-148457

Published: 2021

Journal Articles

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial

Alessandra Tedeschi, Emmanuelle Ferrant, Ian W. Flinn, Constantine S. Tam, Paolo Ghia, Tadeusz Robak, Jennifer R. Brown, Vanitha Ramakrishnan, Tian Tian, Sowmya B. Kuwahara, Jason C. Paik, Aileen Cohen, Jane Huang, Peter Hillmen

Blood (2021) 138 (Supplement 1): 67.

DOI: https://doi.org/10.1182/blood-2021-144336

Published: 2021

Journal Articles

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Paolo Ghia, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Stephen Opat, Ian W. Flinn, Xavier C. Badoux, Alessandra Tedeschi, Eva Gonzalez-Barca, John M. Pagel, Ryan Jacobs, Jacqueline Barrientos, Edith Szafer-Glusman, Cathy Zhou, Joi Ninomoto, James P. Dean, Constantine S. Tam, William G. Wierda

Blood (2021) 138 (Supplement 1): 68.

DOI: https://doi.org/10.1182/blood-2021-144544

Published: 2021

Journal Articles

Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution

Kevin Wang, Maurizio Di Liberto, Yang Hu, Xiangao Huang, Rachel M Koldej, David Ritchie, Peter Martin, Giorgio Inghirami, Olivier Elemento, Constantine S. Tam, Selina Chen-Kiang

Blood (2021) 138 (Supplement 1): 1323.

DOI: https://doi.org/10.1182/blood-2021-152908

Published: 2021

Journal Articles

How I treat chronic lymphocytic leukemia after venetoclax

Thomas E. Lew, Constantine S. Tam, John F. Seymour

Blood (2021) 138 (5): 361–369.

DOI: https://doi.org/10.1182/blood.2020008502

Published: 2021

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Blood (2020) 136 (Supplement 1): 11–12.

DOI: https://doi.org/10.1182/blood-2020-134280

Published: 2020

Journal Articles

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial

Constantine S. Tam, MBBS, MD, Ian W. Flinn, MD PhD, Alessandra Tedeschi, MD, Emmanuelle Ferrant, MD, Jennifer R. Brown, MD PhD, Tadeusz Robak, MDPhD, Paolo Ghia, MD PhD, Sowmya B. Kuwahara, PharmD, Jason C. Paik, MD PhD, Lei Hua, PhD, Aileen Cohen, MD PhD, Jane Huang, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 24–25.

DOI: https://doi.org/10.1182/blood-2020-134179

Published: 2020

Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Blood (2020) 136 (Supplement 1): 16–17.

DOI: https://doi.org/10.1182/blood-2020-134446

Published: 2020

2 3 4 5

NARROW

Single-cell multiomics reveal the scale of multi-layered adaptations enabling CLL relapse during venetoclax therapy

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Clonal hematopoiesis, myeloid disorders and BAX -mutated myelopoiesis in patients receiving venetoclax for CLL

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma

BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies

Real World Data on the Outcomes of Richter's Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution

How I treat chronic lymphocytic leukemia after venetoclax

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only